Caplin Point Laboratories Limited
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
What Caplin files
- Others44
- Investor Meet25
- Updates14
- Important14
- Board Meeting7
- Dividend/Bonus5
Caplin Point is ensuring all shareholders can access its upcoming Annual General Meeting (AGM) and Annual Report. Letters with a weblink are being sent to those without registered emails, enabling online access to key documents.
Company filed its FY26 Business Responsibility and Sustainability Report. It expanded its global footprint by acquiring new subsidiaries in Chile and Mexico. The firm achieved 36.65% renewable power usage and 52.39% water recycling. New sustainability targets aim for 50% solar energy and 45% women's workforce participation. CSR spending reached ₹4.70...
Caplin Point's subsidiary, Caplin One Labs, secured crucial GMP compliance from INVIMA, Colombia. This enables its unit to manufacture sterile & non-sterile oncology drugs like injections, tablets, and capsules. Opens significant market access and growth opportunities in Colombia for these specialized products.
Caplin Steriles (subsidiary) received 10 procedural observations on Form 483 after a US FDA inspection at its Gummidipoondi facility. No data integrity issues or repeat observations. The company is addressing the findings for resolution.
Caplin Point, via its subsidiaries, acquired 10 approved Injectable & Ophthalmic ANDAs from a multinational firm. This strategically boosts its US portfolio, addressing a $473.2 million market, and includes oncology injectables for its new facility, with plans for international expansion.